Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
Medication approved for uUTIs in women and pediatric patients aged 12 years and older
FDA OKs Amvuttra to Treat Heart Conditions
Kennedy Orders Takedown of Fake CDC Vaccine Web Page
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease
Low-Dose Doxycycline Effective for Lymphocytic Scarring Alopecias
Effectiveness with low-dose doxycycline as effective as with high doses, but with greater tolerability
ACP Issues Clinical Guideline for Pharmacologic Treatment of Acute Episodic Migraine
ACP recommends adding triptan to NSAID or acetaminophen to treat moderate-to-severe acute episodic migraine
Microplastics Found in Filtered Solutions Used for Medical IV Infusions
Microplastic particles ranged in size from 1 to 62 µm, with about 90 percent ranging from 1 to 20 µm
Ensitrelvir Effectively Prevents Spread of COVID-19 in Households
In recent study, 9 percent of participants taking placebo developed COVID-19 versus 2.9 percent of people taking ensitrelvir
